Results 111 to 120 of about 1,255,934 (217)
Aspirin vs. P2Y12 Inhibitor Rivalry: Which One Can be Continued During Gastrointestinal Bleeding
Acta Medica Indonesiana, 2019 Dual antiplatelet therapy (DAPT) is the mainstay of secondary prevention treatment for acute coronary syndrome (ACS) and ischemic stroke, especially after coronary intervention. DAPT consists of aspirin and P2Y12 receptor inhibitor (e.g.
Muhammad Begawan Bestari +1 more
doaj +2 more sources
Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone
Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9336-9345, October 2026.ABSTRACT Aims To evaluate whether initiation of amiodarone while receiving sulfonylurea is associated with an increased risk of severe hypoglycemia compared with the initiation of other antiarrhythmic agents (flecainide, sotalol, or propafenone) while receiving sulfonylurea. Materials and Methods We conducted a population‐based cohort study using South
Sungho Bea +5 more
wiley +1 more source
The G(i)-coupled P2Y12 Receptor Regulates Diacylglycerol-mediated Signaling in Human Platelets
, 2008 Stimulation of G(q)-coupled receptors activates phospholipase C and is supposed to promote both intracellular Ca(2+) mobilization and protein kinase C (PKC) activation.
Graziani Andrea +15 more
core +1 more source
Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca
ChemBioChem, Volume 27, Issue 17, 14 September 2026.Biocatalysis is strengthening AstraZeneca's manufacture of active pharmaceutical ingredients through faster development, robust scale‐up, and lower environmental impact. Case studies illustrate where biocatalysis delivers greatest value, while enabling platforms, teams, and partnerships shape its next phase.
Alba Diaz‐Rodriguez +4 more
wiley +1 more source
The DRY motif at work: the P2Y12 receptor case [PDF]
Journal of Thrombosis and Haemostasis, 2014 G. Rovati, V. Capra
openaire +2 more sources
, 2017 Cardiovascular diseases, including in general affections of heart, brain, and blood vessels, are the leading worldwide cause of death with seventeen millions of deaths annually and a third part of them are due to thrombotic events.
Campuzano Maya, Germán
core
Substituted 6-Amino-Thiouracils as new P2Y12 receptor antagonists
, 2007 Platelet adhesion and aggregation are pivotal events in arterial thrombosis thus making platelets the target of several important classes of antithrombotic agents.
BARBARA CACCIARI +5 more
core
P2Y1 and P2Y12 receptors are class A G protein-coupled receptors and previous studies in the Kennedy lab suggested that they may physically interact to form functional heterodimers or possibly higher order oligomers. Little is known, however, about their
Klemm, Nicholas P.
core +2 more sources
P2Y12 inhibitors for acute coronary syndromes: current perspectives
, 2015 James J Nawarskas,1 Cheyenne Newsome,2 Joe R Anderson,1 Bina Ahmed3 1Department of Pharmacy Practice and Pharmacy Administration, The University of New Mexico College of Pharmacy, 2Department of Pharmacy, The University of New Mexico Hospitals ...
Newsome C +3 more
core
The future of P2Y12 receptor antagonists
, 2015 Platelet P2Y12 inhibitors have become a central component of the treatment strategy for patients with atherothrombosis due to the importance of platelet P2Y12 receptors in arterial thrombosis.
Thomas, Mark R; id_orcid +1 more
core +1 more source